# Myofibre Density Reveals a Critical Threshold Around Age 6 in Steroid‐Naïve Duchenne Muscular Dystrophy: A Retrospective Observational Study

## TL;DR

A new study finds that muscle fiber density in Duchenne muscular dystrophy drops sharply until age 6, identifying a key threshold for early disease progression.

## Contribution

The study introduces myofibre density (MFD) as a novel, simple biomarker for early DMD progression and identifies a critical age threshold around 6 years.

## Key findings

- Myofibre density (MFD) declines sharply until age 6 in DMD patients.
- A critical threshold around age 6 was identified using segmented regression and Bayesian modeling.
- MFD provides a reproducible biomarker for early disease progression and potential therapeutic windows.

## Abstract

In Duchenne muscular dystrophy (DMD), robust histological markers for assessing early disease progression remain elusive. We defined myofibre density (MFD) as the count of myofibres per square millimetre, which, in our preliminary survey of DMD muscle biopsies, steeply declined with age (Spearman's ρ: −0.85). We aimed to characterise age‐dependent MFD dynamics in early‐stage DMD.

We retrospectively assessed 46 archival muscle‐biopsy slides (steroid‐naïve; collected > 40 years ago) using semi‐quantitative image analysis with digital restoration. MFD and classical histological variables were quantified. Age–MFD dynamics were modelled with segmented regression and validated using weakly informative Bayesian modelling. The primary measure was the MFD age‐breakpoint. Secondary measures included breakpoint‐detection power, age‐predictive MFD cut‐offs and behaviour of conventional variables across breakpoint‐defined age bands.

After quality and age‐distribution screening, 35 slides (age 1–11 years) were analysed. Segmented regression identified a breakpoint at 6.25 years (95% confidence interval [CI]: 5.08–7.42); after which MFD plateaued at lower levels. Bayesian posterior estimate was 6.37 years (95% credible interval: 5.24–7.66). A 10,000‐run Monte Carlo simulation (n = 35) showed approximately 80% power to recapture the breakpoint within ±1.25 years. MFD cut‐offs > 596 and < 426 fibres/mm2 corresponded to 80% and 20% probabilities of age < 6.25 years. Between the early (< 5 years) and late (≥ 7.5 years) age bands defined by the breakpoint–CI limits, myofibre‐size parameters, myofibre area and fat replacement shifted significantly.

MFD, a simple metric, reveals a previously unrecognised phase of rapid myofibre loss lasting up to around age 6 in early‐stage DMD.

Myofibre density (MFD) reveals a previously unrecognised phase of rapid myofibre loss lasting up to approximately 6 years of age in patients with Duchenne muscular dystrophy (DMD) that could serve as a candidate surrogate biomarker for early disease progression.The identified threshold around age 6 and the observed MFD dynamics delineate a critical histopathological transition in disease progression, thereby providing deeper insights into the natural history of DMD.The original semi‐quantitative image analysis approach, incorporating novel digital restoration techniques (such as look‐up table adjustment and Focus Stacking), effectively captures early subtle tissue alterations, providing a potential framework to inform and enhance clinical decision‐making.

Myofibre density (MFD) reveals a previously unrecognised phase of rapid myofibre loss lasting up to approximately 6 years of age in patients with Duchenne muscular dystrophy (DMD) that could serve as a candidate surrogate biomarker for early disease progression.

The identified threshold around age 6 and the observed MFD dynamics delineate a critical histopathological transition in disease progression, thereby providing deeper insights into the natural history of DMD.

The original semi‐quantitative image analysis approach, incorporating novel digital restoration techniques (such as look‐up table adjustment and Focus Stacking), effectively captures early subtle tissue alterations, providing a potential framework to inform and enhance clinical decision‐making.

We analysed archival muscle biopsies of steroid‐naïve patients with Duchenne muscular dystrophy (DMD), proposing a novel, simple metric: myofibre density (MFD). MFD sharply declines until age 6, identifying a critical threshold around this age. MFD provides a sensitive, reproducible biomarker for early disease progression, highlighting a potential therapeutic window and informing histopathological assessment in DMD.